| Company name | Illumina, Inc. |
| Stock ticker | ILMN |
| Live stock price | [stckqut]ILMN[/stckqut] |
| P/E compared to competitors | Good |
MANAGEMENT EXECUTION
| Employee productivity | Poor |
| Sales growth | Good |
| EPS growth | Good |
| P/E growth | Good |
| EBIT growth | Good |
ANALYSIS
| Confident Investor Rating | Good |
| Target stock price (TWCA growth scenario) | $429.08 |
| Target stock price (averages with growth) | $578.79 |
| Target stock price (averages with no growth) | $393.15 |
| Target stock price (manual assumptions) | $427.13 |
The following company description is from Reuters: https://www.reuters.com/finance/stocks/company-profile/ilmn
Illumina, Inc. (Illumina), incorporated on May 16, 2000, is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc. (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations. Core Illumina’s products and services serve customers in the research, clinical and applied markets, and enable the adoption of a range of genomic solutions. GRAIL is engaged in developing a blood test for early-stage cancer detection. Helix was established to enable individuals to explore their genetic information by providing sequencing and database services for consumers through third-party partners.
The Company’s portfolio of integrated systems, consumables and analysis tools addresses the range of genomic complexity, price points, and throughput, enabling customers to select the solution for their research or clinical challenge. The Company offers its products and services to various customers, including genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, agrigenomics, commercial molecular diagnostic laboratories, and consumer genomics companies. The Company’s products and services enable the adoption of genomic solutions in research and clinical settings. The Company provides reproductive-health solutions, including noninvasive prenatal testing (NIPT), preimplantation genetic screening and diagnosis, and neonatal and genetic health testing. The Company’s technology enables NIPT for early identification of fetal chromosomal abnormalities by analyzing cell-free deoxyribonucleic acid (DNA) in maternal blood. Its preimplantation genetic screening solution is used with in vitro fertilization (IVF) to determine, before implantation, whether an embryo has an abnormal number of chromosomes. Its preimplantation genetic diagnosis technology determines which embryos are free from gene variants associated with genetic diseases.
Confident Investor comments: At this price and at this time, I think that a Confident Investor can confidently invest in Illumina, Inc. as long as the indicators that I describe in my book The Confident Investor are favorable.
If you would like to understand how to evaluate companies like I do on this site, please read my book, The Confident Investor. You can review the best companies that I have found (and I probably invest my own money in most of these companies) in my Watch List.
How was this analysis of Illumina, Inc. calculated?
For owners of my book, “The Confident Investor” I offer the following analysis (you must be logged in to this site as a book owner in order to see the following analysis). If you have registered and cannot see the balance of this article, make sure you are logged in and refresh your browser.
[s2If current_user_can(access_s2member_level1)]
In order to assist you in using the techniques of this book, the values that I used when calculating the Manual pricing above were:
- Stock price at the time of the calculation: $277.75
- Growth: 0.2
- Current EPS (TTM): $4.85
- P/E: 57
- Future EPS Calc: $12.06
- Future Stock Price Calc: $687.89
- Target stock price: $427.12
[/s2If]
I hope that this makes you a Confident Investor.